BACKGROUND: Refractory coeliac disease type I is a complicated form of coeliac disease characterised by primary or secondary resistance to a gluten-free diet with persisting or reoccurring intestinal villous atrophy and symptoms of malabsorption. Besides corticosteroids, azathioprine has been advocated for the treatment of refractory coeliac disease type I. However, tioguanine (TG) might be better tolerated and more efficacious owing to a simpler metabolism towards bioactivation. AIM: To evaluate tolerability and effectiveness of the nonconventional thiopurine derivative TG in refractory coeliac disease type I. METHODS: Refractory coeliac disease type I patients treated with TG between June 2001 and November 2010 with a follow-up period of at least 1 year were included. Adverse events, laboratory values, 6-thioguanine nucleotide concentrations and rates of both clinical and histological response were evaluated at baseline and during follow-up. RESULTS: Twelve adult refractory coeliac disease type I patients were included. The median TG treatment duration was 14 months. Ten patients tolerated TG treatment on the long term, whereas two patients withdrew treatment due to adverse events. No nodular regenerative hyperplasia of the liver was observed. During follow-up clinical and histological response was observed in 83% and 78%, respectively. Corticosteroid dependency decreased by 50%. CONCLUSION: Tioguanine appears to be a convenient drug for the treatment of refractory coeliac disease type I based on higher histological and similar clinical response rates as compared with historical conventional therapies.
BACKGROUND: Refractory coeliac disease type I is a complicated form of coeliac disease characterised by primary or secondary resistance to a gluten-free diet with persisting or reoccurring intestinal villous atrophy and symptoms of malabsorption. Besides corticosteroids, azathioprine has been advocated for the treatment of refractory coeliac disease type I. However, tioguanine (TG) might be better tolerated and more efficacious owing to a simpler metabolism towards bioactivation. AIM: To evaluate tolerability and effectiveness of the nonconventional thiopurine derivative TG in refractory coeliac disease type I. METHODS: Refractory coeliac disease type Ipatients treated with TG between June 2001 and November 2010 with a follow-up period of at least 1 year were included. Adverse events, laboratory values, 6-thioguanine nucleotide concentrations and rates of both clinical and histological response were evaluated at baseline and during follow-up. RESULTS: Twelve adult refractory coeliac disease type Ipatients were included. The median TG treatment duration was 14 months. Ten patients tolerated TG treatment on the long term, whereas two patients withdrew treatment due to adverse events. No nodular regenerative hyperplasia of the liver was observed. During follow-up clinical and histological response was observed in 83% and 78%, respectively. Corticosteroid dependency decreased by 50%. CONCLUSION:Tioguanine appears to be a convenient drug for the treatment of refractory coeliac disease type I based on higher histological and similar clinical response rates as compared with historical conventional therapies.
Authors: Elisabeth Megan Rose Baggus; Marios Hadjivassiliou; Simon Cross; Hugo Penny; Heidi Urwin; Sarah Watson; Jeremy Mark Woodward; David S Sanders Journal: Frontline Gastroenterol Date: 2019-08-08
Authors: Tom van Gils; Petula Nijeboer; Roy L van Wanrooij; Gerd Bouma; Chris J J Mulder Journal: Nat Rev Gastroenterol Hepatol Date: 2015-09-08 Impact factor: 46.802
Authors: Tom van Gils; Tine van de Donk; Gerd Bouma; Foke van Delft; E Andra Neefjes-Borst; Chris J J Mulder Journal: BMJ Open Gastroenterol Date: 2016-06-27
Authors: Terry Sigman; Van-Hung Nguyen; Florin Costea; Ana Sant'Anna; Ernest G Seidman Journal: BMC Gastroenterol Date: 2014-02-13 Impact factor: 3.067